It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Risk evaluation of lymph node metastasis (LNM) for endoscopically resected submucosal invasive (T1) colorectal cancers (CRC) is critical for determining therapeutic strategies, but interobserver variability for histologic evaluation remains a major problem. To address this issue, we developed a machine-learning model for predicting LNM of T1 CRC without histologic assessment. A total of 783 consecutive T1 CRC cases were randomly split into 548 training and 235 validation cases. First, we trained convolutional neural networks (CNN) to extract cancer tile images from whole-slide images, then re-labeled these cancer tiles with LNM status for re-training. Statistical parameters of the tile images based on the probability of primary endpoints were assembled to predict LNM in cases with a random forest algorithm, and defined its predictive value as random forest score. We evaluated the performance of case-based prediction models for both training and validation datasets with area under the receiver operating characteristic curves (AUC). The accuracy for classifying cancer tiles was 0.980. Among cancer tiles, the accuracy for classifying tiles that were LNM-positive or LNM-negative was 0.740. The AUCs of the prediction models in the training and validation sets were 0.971 and 0.760, respectively. CNN judged the LNM probability by considering histologic tumor grade.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Japanese Foundation for Cancer Research, Division of Pathology, Cancer Institute, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Japanese Foundation for Cancer Research, Department of Pathology, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
2 Japanese Foundation for Cancer Research, Department of Endoscopy, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
3 Japanese Foundation for Cancer Research, Department of Colorectal Surgery, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
4 Japanese Foundation for Cancer Research, Division of Pathology, Cancer Institute, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Japanese Foundation for Cancer Research, Department of Pathology, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Japanese Foundation for Cancer Research, Pathology Project for Molecular Targets, Cancer Institute, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)